But starting in 2004, when antiangiogenic therapies first became available, you can see that there has been a 70 to 100 percent improvement in survival for people with kidney cancer, multiple myeloma, colorectal cancer, and gastrointestinal stromal tumors.
Tapi sejak 2004, ketika terapi-terapi antiangiogenik mulai tersedia, anda dapat melihat dengan jelas ada peningkatan waktu hidup pasien dari 70 sampai 100 persen bagi orang yang menderita kanker ginjal, myeloma jamak, kanker usus besar, dan tumor stromal usus.